Chapter 1: What Are Peptides? Amino Acids, Peptide Bonds, and the Molecules Between Small Drugs and Large Proteins

"Nature uses only the longest threads to weave her patterns, so that each small piece of her fabric reveals the organization of the entire tapestry." — Richard Feynman, The Character of Physical Law (1965)

Overview

A peptide is a short chain of amino acids. That is the whole definition, and it is almost useless.

Insulin is a peptide, and it has kept people alive since 1922. Semaglutide is a peptide, and it is the most consequential metabolic drug in fifty years. BPC-157 is a peptide, and as of this writing there is not one completed, peer-reviewed, randomized human trial of it in the published literature. Oxytocin is a peptide, and the sentence "oxytocin is the love hormone" has done more damage to public understanding of neuroscience than almost any other five words. All four statements are true simultaneously.

That is the problem this book exists to solve. You cannot reason about a peptide from the fact that it is a peptide, any more than you can reason about a stranger from the fact that they are a mammal. You have to look at the specific molecule and, more importantly, at the specific evidence.

So we are going to learn to do that — but not yet. First we need the molecule itself, because a surprising number of peptide arguments are settled by chemistry rather than by clinical data. When someone tells you a peptide taken orally will heal your tendon, the fastest way to evaluate that claim is not to look for a trial. It is to know what your stomach does to a chain of amino acids, and that is a Chapter 1 question.

By the end of this chapter you will be able to look at any compound — a drug, a supplement ingredient, a research chemical, a cosmetic additive — and say whether it is a peptide, roughly how big it is, what that size implies about how it must be administered, and what its name is trying to tell you. That is a real diagnostic skill, and it eliminates a startling fraction of bad claims before any evidence is consulted at all.

In this chapter, you will learn to:

• Describe what an amino acid is and explain why the R group is where all the variety lives
• Explain how the peptide bond forms, why it releases water, and why that matters for digestion
• Distinguish primary, secondary, and tertiary structure — and say which one a drug company can control
• Apply the peptide/protein convention correctly, and explain why it is a convention
• Place any molecule on the spectrum from aspirin to a therapeutic antibody
• Explain why the peptide size range produces both extraordinary specificity and extraordinary delivery problems
• Read a peptide's name and extract real information from it

Learning Paths

All five paths read this chapter in full. It is the only foundation the rest of the book assumes.

💊 GLP-1 — pay attention to §1.6 (size and the drug landscape) and §1.8 (drug naming); "-tide" is about to become the most important suffix in your life. 🏋️ Performance — §1.4 (structure) and §1.7 (why size cuts both ways) are the sections that will let you evaluate oral-peptide claims in Part III without needing a single trial. 🔬 Science — read straight through; §1.3 and §1.4 are the chemical foundation for Chapters 32 and 33. 💄 Cosmetic — §1.6 is the section that explains, in advance, why a topical peptide has a physics problem. Chapter 30 is the payoff. 🏥 Clinical — mostly review, but §1.5 and §1.8 are worth reading; they are the two places patients most often get confused, and the confusions are fixable in a sentence each.

1.1 The question behind the question

People do not usually arrive at peptide science out of curiosity about amide bonds. They arrive because of a specific question, and the question is almost always one of four:

My sister started Ozempic and I want to understand what it's doing to her.

My training partner injects something called BPC-157 and says it healed his shoulder. Is that real?

I paid ninety dollars for a serum whose main selling point is "copper peptides." Did I get scammed?

A clinic sent me an email about "peptide therapy for optimization and longevity." Is that medicine or marketing?

Every one of those is a good question. None of them can be answered without first answering a duller one: what kind of thing is a peptide, physically?

Here is why that is not a stalling tactic. Consider the second question. Suppose you want to evaluate whether an oral BPC-157 capsule could heal a shoulder tendon. You could go looking for trials — and you should, and Chapter 17 does. But before that, there is a much faster check available, and it requires only chemistry:

1. A peptide is a chain of amino acids joined by a particular kind of bond.
2. Your digestive system contains enzymes whose entire evolved purpose is to break that exact bond, because that is how you extract amino acids from the protein in your food.
3. Therefore, a peptide swallowed on an empty stomach is, by default, food.

That does not close the question — there are real strategies for protecting a peptide from digestion, and Chapter 4 covers them, and one of them produced an actual approved oral drug. But it changes what you are looking for. You are no longer asking "does this compound heal tendons?" You are asking "how does this compound survive the stomach, and can whoever is selling it explain that?" That question has a much shorter list of acceptable answers, and most sellers cannot give one.

This is the pattern for the whole book. Chemistry narrows the space of plausible claims. Evidence decides among what remains. People who skip the first step spend a lot of energy debating claims that were never physically available in the first place.

🔍 Check Your Understanding

1. Why does knowing that digestive enzymes break peptide bonds help you evaluate an oral peptide claim before you have looked at any evidence?
2. What would a seller need to explain for an oral peptide claim to remain plausible?

1.2 Amino acids: twenty building blocks and the R group that makes each one different

Everything in this book is built from twenty molecules.

An amino acid has a fixed core and one variable part. The core is the same in every single one: a central carbon atom carrying an amino group ($-NH_2$), a carboxyl group ($-COOH$), and a hydrogen atom. Attached to that same central carbon is the fourth thing — the R group, also called the side chain — and that is where all the variety lives.

THE AMINO ACID — one shape, twenty variations
                     R          ← the side chain: THIS is what differs
                     |
        H2N — — — —  C  — — — — COOH
       amino         |          carboxyl
       group         H          group
                (alpha carbon)

  The amino group and the carboxyl group are identical in all twenty.
  Change R and you change everything about how this molecule behaves.

Twenty different R groups. That is the entire alphabet of proteins and peptides across all known life, with two rare exceptions that are worth a footnote and not a chapter. (Selenocysteine and pyrrolysine are genuinely incorporated during protein synthesis in some organisms, which is why you will occasionally see "22 amino acids." For everything in this book, it is twenty.)

The side chains sort naturally into a few families, and knowing the families is enough — nobody needs to memorize twenty structures to read this book.

Four properties worth remembering specifically, because they will each earn their keep later:

Cysteine can form a bridge. Its side chain ends in a sulfur atom, and two cysteines can link to each other through that sulfur, forming a disulfide bond. This is the closest thing biology has to a staple. Insulin's two chains are held together by exactly this, and without those bridges insulin is not insulin (Chapter 11).

Proline breaks helices. Its side chain loops back and bonds to the backbone nitrogen, which makes that part of the chain rigid and unable to participate in the regular hydrogen bonding that forms an alpha helix. Proline is a structural comma. It appears repeatedly in BPC-157, which is one reason that molecule's shape is unusual (Chapter 17).

Lysine is the handle. Its side chain ends in a free amino group that chemists can attach things to without disturbing the rest of the molecule. When a drug company wants to hang a fatty acid off a peptide to extend its half-life, lysine is where they hang it — and semaglutide is exactly that story (§1.6, Chapter 33).

Glycine is the hinge. Its R group is a single hydrogen atom, the smallest possible. That makes glycine unusually flexible and lets a chain turn corners that no other residue permits.

🧬 The Molecule — why twenty, and why these twenty?

Twenty is a strange number. It is not obviously optimal, and there are dozens of other amino acids in nature that life does not use in proteins.

The honest answer is that nobody fully knows. The most-supported account is that the set is largely a frozen accident — an early biochemical choice that became impossible to revise once the entire machinery of translation was built around it. Adding a twenty-first amino acid to the universal genetic code would require changing the code itself, and every organism that tried would mistranslate every protein it makes.

What is clear is that the twenty span an unusually wide range of chemical properties for such a small set: acidic to basic, greasy to water-loving, tiny to bulky, rigid to floppy. Whether that range was selected for or simply turned out to be sufficient is one of those questions where the honest position is that we have plausible stories and not much resolving power between them.

This is a good place to notice something about how this book will operate. That paragraph could easily have been written as "the twenty amino acids were selected by evolution for optimal chemical diversity" — which sounds authoritative, is widely repeated, and is a hypothesis rather than a finding. Watch for that construction. It shows up constantly in peptide marketing, where a plausible story about why something should work routinely stands in for evidence that it does.

1.3 The peptide bond: how a chain gets built

Two amino acids join by a condensation reaction — the carboxyl group of one reacts with the amino group of the next, they link, and a molecule of water is released. The resulting link is the peptide bond.

THE PEPTIDE BOND — a condensation reaction
       amino acid 1                     amino acid 2
   H2N–CH(R1)–C(=O)–OH        +      H–NH–CH(R2)–COOH
                    └──────── −H2O ────────┘
   H2N–CH(R1)–C(=O)–NH–CH(R2)–COOH          ← the peptide bond is the C(=O)–NH link
        └── N-terminus                  C-terminus ──┘

   Two amino acids, one water molecule released, one bond formed. Repeat 29 more times
   and you have GLP-1. Repeat 50 more and you have insulin. Repeat 190 more and you have
   growth hormone — at which point most people stop saying "peptide" and start saying
   "protein," for reasons that are conventional rather than chemical.

Three consequences follow from this, and each one matters later.

The chain has direction. One end retains a free amino group — the N-terminus — and the other retains a free carboxyl group — the C-terminus. By universal convention, sequences are written and numbered N-terminus first. When Chapter 8 tells you that semaglutide is modified at position 8, that means the eighth amino acid counting from the N-terminal end. Getting the direction backwards makes a sequence describe a completely different molecule.

Once an amino acid is incorporated into a chain, it is called a residue — because in joining, it gave up the atoms that became water. It is what remains. A "15-residue peptide" and a "15-amino-acid peptide" mean the same thing.

The bond is reversible, and your body reverses it constantly. Condensation released water; adding water back — hydrolysis — breaks the bond. Enzymes called proteases or peptidases do this with great efficiency, and you are full of them. Pepsin in your stomach, trypsin and chymotrypsin from your pancreas, peptidases lining your intestine, and more in your bloodstream, liver, and kidneys.

This is not incidental. It is the central fact of peptide pharmacology. Your body is very good at destroying peptides, because destroying peptides is how you eat. Every peptide drug in this book is, at some level, an answer to the question of how to survive that. Chapter 4 is entirely about the answers.

The backbone is rigid; the side chains are not. The peptide bond has partial double-bond character, which means it does not rotate freely — the six atoms around each peptide bond sit in a plane. Rotation happens at the bonds on either side. The result is a chain that is neither a rigid rod nor a floppy string, but something with constrained, predictable flexibility. That constraint is what makes folding possible at all. A truly floppy chain could not reliably adopt one shape, and a truly rigid one could not adopt any.

⚠️ Hype Check — "peptides are natural, so they're safe"

The claim, in its usual form:

"Peptides aren't drugs — they're natural signaling molecules your body already makes. That's why they're so safe compared to pharmaceuticals."

What's true in it. Many peptide drugs are based on molecules the body genuinely produces, and "the body already knows what to do with this" is a real design advantage. Peptides also tend not to accumulate in tissue the way some small molecules do, because they are broken down into ordinary amino acids. Those are legitimate points.

Where it fails. Three places, and each is a chemistry question you can now answer.

First, "natural" is doing no work. Botulinum toxin is natural. So is ricin. So is the venom peptide in a cone snail that is the basis for an approved analgesic so potent it must be delivered directly into spinal fluid. Being produced by a living thing predicts nothing about safety.

Second, most peptide drugs are not the natural molecule. Semaglutide differs from human GLP-1 at two positions and carries a synthetic fatty acid chain — deliberately, so your enzymes cannot recognize and destroy it. That modification is the entire point, and it means the molecule is precisely not the thing your body already knows how to handle. A drug engineered to resist degradation is a drug that persists, and persistence is where side effects live.

Third, the natural version arrives on a schedule your body controls — in pulses, at specific concentrations, in specific tissues, terminated on cue. An injection is a flat, sustained, whole-body exposure that no physiological system ever produces. Chapter 3 shows why that difference is often the whole difference between a hormone and a drug.

Verdict: the claim confuses provenance with safety. Safety is established by testing a specific molecule at a specific exposure in a specific population, and no amount of naturalness substitutes.

1.4 From chain to shape: primary, secondary, and tertiary structure

A peptide is not a piece of string. It has a shape, that shape is largely determined by the sequence, and the shape is what a receptor actually recognizes.

Biochemists describe this in levels.

Primary structure is the sequence — which amino acids, in which order. This is the information content, and it is what a gene encodes. Everything downstream follows from it.

Secondary structure is local, regular folding of the backbone, held by hydrogen bonds. Two patterns dominate.

THE TWO MAIN SECONDARY STRUCTURES

  ALPHA HELIX — the backbone coils; side chains point outward
       ___                         · roughly 3.6 residues per turn
      /   \___                     · hydrogen bonds run ALONG the helix,
     |        \___                   from each residue to the one four ahead
      \   ___/    \___             · a rigid, compact rod
       \_/    \___/                · the most common shape in peptide hormones
        R  R  R  R  R              · proline interrupts it (see 1.2)

  BETA SHEET — strands lie alongside each other; the sheet pleats
     →→→→→→→→→→→→→→→              · hydrogen bonds run BETWEEN strands
     ‖ ‖ ‖ ‖ ‖ ‖ ‖ ‖ ‖              · strands can run the same way or opposite
     →→→→→→→→→→→→→→→              · flat and extended rather than coiled
     ‖ ‖ ‖ ‖ ‖ ‖ ‖ ‖ ‖              · common in structural and antimicrobial peptides
     →→→→→→→→→→→→→→→

  RANDOM COIL — no regular repeating pattern. NOT disorder without consequence:
  many short peptides are largely coil in water and only adopt a defined shape
  when they meet their receptor or a membrane. Shape can be something a peptide
  ACQUIRES on arrival rather than something it carries.

That last point is easy to skip and worth pausing on. A great many small peptides are floppy in solution and only fold when they bind. Their shape is not a property of the molecule alone; it is a property of the molecule plus its target. This is why "the peptide's structure" is sometimes a misleading phrase, and why predicting what a short peptide will do from its sequence alone is much harder than the equivalent problem for a large, stably folded protein.

Tertiary structure is the overall three-dimensional arrangement — how the helices and sheets and coils pack against each other in space. For a large protein this is elaborate. For a 30-residue peptide it may be as simple as "one helix with flexible ends." Tertiary structure is stabilized by hydrophobic packing, hydrogen bonds, salt bridges, and — where cysteines are present — disulfide bonds.

Quaternary structure, where multiple separate chains assemble, appears in this book mainly for insulin, which stores as a zinc-coordinated hexamer and must come apart into single molecules before it can act. That storage form is why "rapid-acting insulin" is a real engineering achievement rather than a marketing term (Chapter 11).

Why the levels matter for drugs

Here is the practical translation, and it is one of the most useful frames in the book:

Sequence is what a drug company controls. Shape is what a receptor sees. Everything in peptide engineering happens in the gap between them.

Change one residue and you may change nothing, or you may abolish activity entirely, or you may make the molecule invisible to the enzyme that used to destroy it. Which of those happens depends on whether the residue you touched was doing structural work, receptor-contact work, or nothing much.

Semaglutide is the clean example, and you will meet it repeatedly. The change at position 8 does not alter what GLP-1 does — it alters whether the enzyme DPP-4 can recognize the molecule as a substrate. Same activity, radically different lifetime. That is a structural intervention aimed at a pharmacokinetic problem, and Chapter 33 shows the whole toolkit.

🧬 The Molecule — reading a sequence

Peptide sequences are written N-terminus to C-terminus in one of two codes.

Three-letter code, which is readable: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp… One-letter code, which is compact: HAEGTFTSD…

Both describe the same thing. The one-letter code is standard in databases and papers; the three-letter code is standard in teaching and in patent documents. Appendix I gives the full mapping and the conventions for describing modifications.

A worked example. BPC-157 is written as:

text Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val G E P P P G K P A D D A G L V 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Fifteen residues. Now read it with §1.2 in hand and it starts talking. Four prolines (positions 3, 4, 5, 8), including a run of three — this molecule cannot form a normal alpha helix through that region and is structurally rigid there. Three glycines for flexibility. Two aspartates and one glutamate, so it carries negative charge. One lysine at position 7 — the potential attachment handle.

You now know something real about this molecule from fifteen letters, without any biology at all. Whether it heals anything in a human is an entirely separate question with an entirely separate answer, and Chapter 17 gives it.

1.5 Peptide or protein? A useful convention, not a law of chemistry

The most common definition you will meet is:

• Peptides: roughly 2 to 50 amino acids
• Proteins: roughly 50 or more

That is a real convention, it is genuinely useful, and it is not a chemical distinction. There is no bond that changes at residue 51. A 49-residue chain and a 51-residue chain are the same kind of object. The line is drawn by people, for convenience, and different people draw it in different places — some at 30, some at 40, some at 100.

Additional vocabulary you will encounter:

• Oligopeptide — a short one, usually under about 20 residues
• Polypeptide — a long chain, used either as a synonym for protein or for a chain that has not folded into a functional protein
• Dipeptide, tripeptide, pentapeptide, pentadecapeptide — precise counts. BPC-157 at 15 residues is a pentadecapeptide, and you will see it described that way

Which means several molecules in this book sit awkwardly on the line, and every one of those awkwardnesses has been used in an argument by somebody:

Why does this matter? Because the ambiguity gets exploited in both directions.

In one direction, marketing: calling something a "peptide" borrows the credibility of insulin and semaglutide for a molecule that has nothing else in common with them. This is the most common rhetorical move in the entire consumer peptide space, and it is why this book's thesis is that the category carries no evidentiary weight.

In the other direction, dismissal: "growth hormone isn't really a peptide, it's a protein" is used to wave away comparisons that are actually apt. It is 191 residues, it is made of amino acids joined by peptide bonds, and it is called a peptide hormone throughout the endocrine literature.

The correct posture: when someone leans on the word peptide to make an argument, ask what work they think the word is doing. Almost always the honest answer is "none," and the real question — what does this specific molecule do, and what is the evidence — is still sitting there untouched.

🔍 Check Your Understanding

1. Is a 55-amino-acid chain a peptide or a protein? What is the honest answer?
2. Insulin is 51 amino acids in two chains. Why do reputable sources call it both a peptide hormone and a small protein?
3. Someone says "BPC-157 is a peptide, just like insulin, so it's well understood." Name two distinct errors in that sentence.

1.6 Where peptides sit in the drug landscape

Now the frame that organizes the whole field. Therapeutic molecules span an enormous size range, and size determines nearly everything about how a drug can be given, where it can go, and what it can do.

THE SIZE SPECTRUM OF THERAPEUTIC MOLECULES        (Da = daltons, atomic mass units)

  SMALL MOLECULES              PEPTIDES                    PROTEINS / BIOLOGICS
  100–900 Da                   500–5,000 Da                >5,000 Da, often >100,000

  aspirin        180 Da  │
  metformin      129 Da  │
  atorvastatin   559 Da  │
  ───────────────────────┼──────────────────────────┐
                         │  oxytocin      1,007 Da  │
                         │  BPC-157       1,419 Da  │
                         │  bremelanotide 1,025 Da  │
                         │  octreotide    1,019 Da  │
                         │  teriparatide  4,118 Da  │
                         │  semaglutide  ~4,100 Da  │
                         │  tirzepatide  ~4,800 Da  │
                         │  insulin      ~5,800 Da  │
                         └──────────────────────────┼───────────────────────────
                                                    │  growth hormone   ~22,000 Da
                                                    │  erythropoietin   ~30,000 Da
                                                    │  trastuzumab     ~148,000 Da

  ORAL?     small: usually yes    peptides: usually no     proteins: essentially never
  TARGET    often an enzyme       usually a receptor       usually a receptor or another protein
  MADE BY   chemical synthesis    synthesis OR cells       living cells, almost always
  COST      cents to dollars      dollars to hundreds      hundreds to thousands

The three regions differ in kind, not just degree.

Small molecules are compact enough to be absorbed from the gut, to diffuse across cell membranes, and often to cross into the brain. They can reach targets inside cells, which is a large part of why so many of them exist. Their weakness is selectivity: a small molecule has few contact points with its target, so it frequently binds things it was not aiming at. That is where a great many side effects come from.

Large biologics — antibodies, enzymes, engineered proteins — are exquisitely selective. An antibody can distinguish between two nearly identical proteins on a cell surface. But they are far too large to be absorbed orally, they cannot enter cells or cross into the brain, they must be produced in living cell cultures, and they cost accordingly.

Peptides sit between, and inherit an unusual mixture from both sides:

• Specificity approaching a biologic. A 30-residue peptide makes many simultaneous contacts with its receptor. It can be extremely selective, which is why peptide drugs often have cleaner target profiles than small molecules.
• Potency at very low concentrations. Peptide hormones commonly act at picomolar to nanomolar concentrations — vanishingly small amounts. That is a consequence of receptor signaling amplification, which Chapter 2 explains.
• Synthesizable chemically. Unlike an antibody, a peptide of moderate length can be built step-by-step in a machine. This is what makes both legitimate manufacturing and the gray market possible, and Chapter 32 covers both.
• Broken down into amino acids. Peptides are metabolized into their components rather than into novel chemical species, so they generally do not produce the reactive metabolites that cause some small-molecule toxicity.

And they inherit the disadvantages too:

• Digested if swallowed. The default route is injection.
• Cleared quickly. Small enough to be filtered by the kidney, and exposed to proteases everywhere.
• Cannot readily enter cells or the brain. Peptide targets are overwhelmingly on cell surfaces. Intracellular targets are largely off-limits, and the blood-brain barrier is the reason Part IV is a story of near-misses.
• Can provoke an immune response. Anything protein-like may be recognized as foreign.

💊 In the Clinic — why almost everything here is an injection

Look at any list of approved peptide medicines and one thing is immediately visible: nearly all of them are injected. Subcutaneously, usually — a small needle into the fat layer under the skin, from which the drug is absorbed over hours.

This is not a preference. It is the consequence of §1.3. A peptide swallowed on an empty stomach meets pepsin, then pancreatic proteases, then the peptidases of the intestinal lining. Very little survives, and what survives is generally too large to cross the intestinal wall.

The exceptions are informative rather than encouraging. Oral semaglutide exists and works, but it required an absorption-enhancing excipient, achieves roughly 1% bioavailability, and must be taken on an empty stomach with a small sip of water followed by a waiting period before anything else is consumed. The tablet contains far more drug than the injection because ninety-nine percent of it is expected not to make it. Some peptides that act within the gut — like linaclotide for constipation — are given orally precisely because they are not supposed to be absorbed at all.

Keep this in mind for Part III. When a product is sold as an oral or sublingual or transdermal version of a peptide that pharmaceutical companies deliver by injection, the burden is on the seller to explain what they solved that the industry did not. Sometimes there is an answer. Usually the question has not been asked.

1.7 Why the middle is interesting: specific enough to be a signal, small enough to build

There is a reason evolution uses peptides for signaling and a reason the pharmaceutical industry spent decades trying to turn them into drugs.

Specificity. A peptide has enough surface area and enough distinct side chains to make a selective fit with a receptor. Oxytocin and vasopressin differ at two of nine positions, and they do substantially different things — oxytocin drives uterine contraction and milk ejection, vasopressin drives water retention and vasoconstriction. Two atoms' worth of difference, two different physiologies. No small molecule achieves that resolution reliably.

Potency. Because peptide receptors amplify — one bound molecule triggers a cascade producing thousands of downstream events — peptide hormones work at concentrations far below what a small molecule typically needs. Your circulating GLP-1 is present at picomolar levels. That is roughly one molecule per trillion water molecules, and it is enough to change what your pancreas does.

Regulation. Because peptides are made on demand and destroyed within minutes, a peptide signal can be turned on and off with precision that a long-lived molecule cannot match. Your body can raise GLP-1 sharply when food arrives and have it gone before the next decision. Chapter 3 explores what happens when a drug replaces that dynamic signal with a flat one.

Buildability. This one is practical rather than biological, and it changed everything. Since Merrifield's method in 1963, peptides of moderate length can be assembled on a machine. That is why peptide drug development is accessible to smaller companies than antibody development — and it is also why an unregulated market exists. The barrier to synthesizing a peptide is much lower than the barrier to producing a monoclonal antibody, and low barriers cut both ways.

The same properties, read as problems

Everything in that list has a shadow.

Specificity means a small change can abolish activity — so a manufacturing error that swaps one residue produces a molecule that looks nearly identical on a scale and does nothing. Potency means dosing errors matter enormously; the difference between a therapeutic and an excessive dose can be small in absolute terms. Tight regulation means the body will respond to a sustained artificial signal by adjusting — downregulating receptors, suppressing its own production (Chapter 3). Buildability means a compound with no human safety data can be manufactured cheaply and sold at scale before anyone has studied it, which is Chapter 19.

🩺 Safety and Risk — what "peptides are broken down into amino acids" does and does not mean

You will encounter this reassurance often, usually in this form: peptides are just amino acids, and your body handles amino acids all day, so the worst case is nothing happens.

What is true: peptides are generally cleared by proteolysis into constituent amino acids and short fragments, which enter normal metabolism. Peptides usually do not accumulate in fat or produce the reactive metabolites behind some small-molecule liver toxicity. As a class, this is a genuine and underappreciated safety advantage.

What it does not mean:

Effects happen before breakdown. The molecule acts at a receptor, and the receptor does not care that the ligand will eventually be recycled. A peptide that inappropriately activates a growth pathway has done so long before it is degraded.

Breakdown products are not always inert. Some peptide fragments have their own biological activity, occasionally different from the parent molecule's.

Nothing about this covers what else is in the vial. Purity, sterility, endotoxin, residual synthesis solvents, and heavy metals are entirely separate questions from what happens to the peptide itself. This is where the actual documented harm in the unregulated market has occurred — not from exotic peptide toxicity, but from contamination, wrong identity, and wrong concentration. Chapters 19 and 34 cover it in detail.

And it says nothing about long-term signaling. Chronic activation of a pathway is a different question from acute exposure, and it is the question we have the least data on for almost every compound in Part III.

As always: decisions about any of this belong with a clinician who knows your history, not with a book.

1.8 How to read a peptide's name

Drug names look arbitrary. They are not. Generic names are assigned under international conventions that encode real information in a stem — a suffix or infix shared by drugs of the same class. Learning a dozen stems means you can often infer a molecule's class from a name you have never seen.

Two of those pairs are worth memorizing outright.

"-relin" versus "-relix." One letter, opposite actions. A -relin compound stimulates a releasing-hormone receptor; a -relix compound blocks it. In prostate cancer treatment this is the difference between a drug that causes an initial testosterone surge before suppression and one that suppresses immediately (Chapter 27).

"-tide" versus "-mab." Peptide versus antibody. Wildly different size, manufacturing, cost, half-life, and delivery. If you see -mab, you are looking at a molecule roughly thirty times the mass of a peptide, produced in cell culture, and administered by injection or infusion.

Beyond generic names, three other naming systems appear in this book, and mixing them up causes real confusion:

Brand names are marketing property, and one molecule can have several. Semaglutide is sold as Ozempic, Wegovy, and Rybelsus — same active molecule, different doses, formulations, and approved indications. People routinely believe Ozempic and Wegovy are different drugs. They are the same drug with different labels, and the difference in approved indication is the thing that actually matters for insurance coverage (Chapter 12).

Research codes are internal identifiers that sometimes stick. BPC-157 and TB-500 and CJC-1295 and MK-677 are all codes, not generic names, and that is itself informative: a compound that never received a generic name almost certainly never completed formal drug development. The naming authority assigns a stem name when a compound is in serious clinical development. A molecule still known only by a laboratory code, decades after its discovery, is telling you something about its regulatory history.

INCI names govern cosmetic ingredients and follow entirely different rules. "Palmitoyl pentapeptide-4" and "acetyl hexapeptide-8" are INCI names, and they describe a modification and a length rather than identifying a specific well-characterized drug substance. Chapter 30 covers what that does and does not tell you.

🔍 Check Your Understanding

1. You encounter a compound called "tesamorelin." From the name alone, what class is it likely in, and what does it probably do?
2. "Degarelix" and "leuprorelin" both act on the same receptor. From their names, how do their actions differ?
3. Why is it informative that BPC-157 has never been given a generic drug name?

1.9 What this book will and will not do

One section of ground rules, because they shape how everything after this reads.

This book explains science. What peptides are, how they work, what has been tested, what the results were, and how to evaluate all of it yourself.

It does not give medical advice, and it contains no protocols. No doses, no preparation, no technique, no cycles, no vendors. Where a dose appears — a trial's dose arms, an approved label's schedule — it is reported as a description of what was studied or what a label says, never as guidance. This is a design constraint, not an oversight, and the project's build validator flags any passage that reads like an instruction sheet.

The reason is straightforward. A book does not know your history, cannot order your labs, cannot see the interaction with the medication you did not mention, and is not available at two in the morning when something goes wrong. A clinician can be all four. Chapter 39 is entirely about making that conversation useful.

It rates every claim it makes, and it names what would change each rating. The system is introduced formally in Chapter 5 and applied for the remaining thirty-five chapters:

Two rules about ratings that will save you a great deal of confusion later:

A rating attaches to a claim, not to a molecule. Semaglutide for weight loss in obesity is ✅. Semaglutide for Alzheimer's disease is 🔬. Same molecule, two claims, two different states of evidence, two ratings. Any source that gives a molecule one overall rating has compressed away the information you need.

A ❌ is a statement about evidence, not about a molecule's potential. It means the confident version of a claim is not supported by human data. It does not mean "does not work." Several ❌ compounds in this book may well be ⚠️ or ✅ in a decade; some will be shown not to work. Both futures are live, and the point is that you will be able to tell which happened when the data arrives.

No ratings are issued in this chapter. That is deliberate. You cannot rate a molecule — only a claim about one — and we have not made any claims yet. Chapter 5 is where the machinery starts.

📋 Your Evidence Dossier

This chapter opens the project you will build across the whole book.

The Peptide Evidence Dossier is a personal reference on the peptides you actually care about. By Chapter 40 you will have complete twelve-field entries on each, plus — far more durably — the habit that produced them. Appendix C is the blank workbook.

Step 1 — Choose your peptides

Pick 5 to 10. Choose the ones you have genuinely wondered about, not the ones you think a serious person should pick. Semaglutide because your sister started it. BPC-157 because your training partner swears by it. Copper peptides because there is a \$90 bottle in your bathroom. Growth hormone because a clinic emailed you. The project only works if the entries matter to you.

If you have no particular attachments, a reasonable starter set that spans the whole evidence range: semaglutide, insulin, BPC-157, oxytocin, GHK-Cu. Those five will end up in four different rating tiers, which makes the contrast do the teaching.

Step 2 — Fill in Field 1 (Identity) for each

Just Field 1. Not what it does — that is Chapter 2. Not whether it works — that is Chapter 5.

FIELD 1 — IDENTITY
  Common name           the name you know it by
  Other names           brand names, research codes, INCI names, generic name if any
  Class                 peptide hormone / analog / synthetic peptide / fragment / not actually a peptide
  Length                number of amino acids (or "unknown — cannot find a stated sequence")
  Molecular weight      in daltons, approximately
  Sequence available?   yes / no / conflicting sources

Worked demonstration — two entries, deliberately opposite

FIELD 1 — INSULIN                            [worked demonstration]
  Common name        Insulin (human insulin; many analogs)
  Other names        insulin lispro, aspart, glargine, detemir, degludec (analogs);
                     Humalog, Novolog, Lantus, Levemir, Tresiba (brands)
  Class              Peptide hormone, endogenous; therapeutic versions are recombinant
                     human insulin or engineered analogs
  Length             51 amino acids in two chains (A = 21, B = 30), disulfide-linked
  Molecular weight   ~5,800 Da
  Sequence available Yes. Fully characterized since the 1950s; in every reference database

FIELD 1 — BPC-157                            [worked demonstration]
  Common name        BPC-157
  Other names        "Body Protection Compound-157"; PL 14736; Pentadecapeptide BPC 157
  Class              Synthetic peptide, described as derived from a sequence found in
                     human gastric juice. NOT an approved drug in any major jurisdiction
  Length             15 amino acids (pentadecapeptide)
  Molecular weight   ~1,419 Da
  Sequence available Yes — GEPPPGKPADDAGLV — and it is consistent across sources.
                     NOTE: a known sequence tells you what the molecule IS. It tells you
                     nothing about whether a given vial contains it (Chapter 34)

Notice what Field 1 already reveals. Both entries are complete and neither required any judgment. And yet one difference is already visible: insulin has a generic name assigned by an international naming authority; BPC-157 has a laboratory code. Per §1.8, that gap is not cosmetic. It is a fact about regulatory history, visible before a single piece of clinical evidence has been consulted.

Step 3 — Note what you already believe

For each peptide, write one sentence on what you currently think it does and how confident you are, on a scale of 1 to 10.

Do this now, before you learn anything else, and date it. You will return to it in Chapter 40. This is the single most uncomfortable and most valuable part of the project, because the interesting finding is rarely that you were wrong — it is discovering which direction you were wrong in, and whether you were consistently more generous toward the compounds you wanted to work.

Everybody has that bias. Very few people can name theirs.

Conclusion

A peptide is a chain of amino acids joined by peptide bonds — usually somewhere between two and fifty of them, though the boundary is a convention rather than a chemical fact. Twenty side chains supply all the variety. The bond forms by releasing water and is broken by adding it back, which is exactly what your digestive enzymes do for a living. The chain has a direction, is numbered from the N-terminus, and folds into shapes that a receptor recognizes.

That size range — between small molecules and biologics — buys a specific set of properties. Peptides can be highly selective and extraordinarily potent, they can be built chemically rather than grown in cells, and they break down into ordinary amino acids. They also cannot usually be swallowed, do not last long, cannot get into cells or the brain, and can occasionally provoke an immune response. Every peptide drug you meet in this book is, at bottom, someone's answer to that trade-off.

And nothing in this chapter told you whether any specific peptide works.

That is the point. The word peptide tells you about chemistry, size, and delivery constraints. It tells you nothing at all about efficacy. Insulin and BPC-157 are both peptides; one has a century of clinical evidence and one has never completed a randomized human trial. That difference is invisible at the level of chemistry and total at the level of evidence.

Chapter 2 takes the next step: what happens when one of these molecules finds its receptor. That is where peptides stop being interesting chemistry and start being signals — and where you will learn the discipline that governs the rest of the book, which is that knowing how something would work is not evidence that it does.

Key Terms

Amino acid — the building block of peptides and proteins: a central carbon bearing an amino group, a carboxyl group, a hydrogen, and a variable R group. Twenty are used in human biology.

R group (side chain) — the variable portion of an amino acid, attached to the alpha carbon. It determines whether a residue is greasy, water-loving, charged, bulky, or flexible.

Peptide bond — the covalent link between the carboxyl group of one amino acid and the amino group of the next, formed by a condensation reaction that releases water.

Condensation reaction — a reaction joining two molecules with the release of water. Hydrolysis is its reverse, and it is how peptides are broken down.

N-terminus — the end of a peptide chain with a free amino group. Sequences are written and numbered from here.

C-terminus — the end of a peptide chain with a free carboxyl group.

Residue — an amino acid once incorporated into a chain, so called because it is what remains after the condensation reaction.

Sequence — the order of amino acids in a chain, written N-terminus to C-terminus. Also called primary structure.

Primary structure — the amino acid sequence itself; the information content of a peptide.

Secondary structure — local regular folding of the backbone held by hydrogen bonds, principally alpha helices and beta sheets.

Alpha helix — a coiled secondary structure, about 3.6 residues per turn, with side chains projecting outward. The most common shape in peptide hormones.

Beta sheet — an extended, pleated secondary structure formed by strands hydrogen-bonded alongside each other.

Tertiary structure — the overall three-dimensional shape of a folded chain.

Disulfide bond — a covalent link between the sulfur atoms of two cysteine residues; biology's staple, holding shapes and chains together.

Dalton (Da) — the unit of molecular mass. Aspirin is 180 Da; insulin is about 5,800 Da; a therapeutic antibody is about 148,000 Da.

Peptide — conventionally, a chain of roughly 2–50 amino acids. The boundary is a convention, not a chemical distinction.

Protein — conventionally, a chain of roughly 50 or more amino acids, usually folded into a defined functional structure.

Polypeptide — a long amino acid chain; used either as a synonym for protein or for an unfolded chain.

Analog — a molecule deliberately modified from a natural one to change its properties while preserving its activity. Semaglutide is a GLP-1 analog.

Endogenous — produced within the body. The opposite, administered from outside, is exogenous.

Proteolysis — enzymatic breakdown of peptide bonds. Carried out by proteases and peptidases, and the reason most peptides cannot be swallowed.

Spaced Review

1. A friend says they are taking an oral supplement containing a peptide "identical to the injectable version used in clinics." Using only §1.3, what is the first question you would ask, and why does the answer matter more than any testimonial?

2. Oxytocin and vasopressin are both nine amino acids long and differ at two positions, yet they produce substantially different physiological effects. Which structural level (§1.4) does that difference live at, and what does it suggest about how sensitive peptide activity is to sequence?

3. Rank these by molecular weight from smallest to largest: insulin, aspirin, trastuzumab, BPC-157, growth hormone. Then state which of them could plausibly be given as a tablet, and why.

4. You see a new compound called "vosoritide." From the name alone (§1.8), what class would you provisionally place it in, and what would you check next to confirm?

5. Explain to someone with no science background, in three sentences, why "it's a peptide, so it's natural and safe" is not a good argument. Do not use any term you have not defined for them first.